These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. Marth K, Breyer I, Focke-Tejkl M, Blatt K, Shamji MH, Layhadi J, Gieras A, Swoboda I, Zafred D, Keller W, Valent P, Durham SR, Valenta R. J Immunol; 2013 Apr 01; 190(7):3068-78. PubMed ID: 23440415 [Abstract] [Full Text] [Related]
5. Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments. Gadermaier E, Marth K, Lupinek C, Campana R, Hofer G, Blatt K, Smiljkovic D, Roder U, Focke-Tejkl M, Vrtala S, Keller W, Valent P, Valenta R, Flicker S. Allergy; 2018 Jul 01; 73(7):1425-1435. PubMed ID: 29315611 [Abstract] [Full Text] [Related]
6. Bet v 1--a Trojan horse for small ligands boosting allergic sensitization? Asam C, Batista AL, Moraes AH, de Paula VS, Almeida FC, Aglas L, Kitzmüller C, Bohle B, Ebner C, Ferreira F, Wallner M, Valente AP. Clin Exp Allergy; 2014 Aug 01; 44(8):1083-93. PubMed ID: 24979350 [Abstract] [Full Text] [Related]
7. Isolation of nanobodies with potential to reduce patients' IgE binding to Bet v 1. Zettl I, Ivanova T, Strobl MR, Weichwald C, Goryainova O, Khan E, Rutovskaya MV, Focke-Tejkl M, Drescher A, Bohle B, Flicker S, Tillib SV. Allergy; 2022 Jun 01; 77(6):1751-1760. PubMed ID: 34837242 [Abstract] [Full Text] [Related]
15. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization. Movérare R, Westritschnig K, Svensson M, Hayek B, Bende M, Pauli G, Sorva R, Haahtela T, Valenta R, Elfman L. Int Arch Allergy Immunol; 2002 Aug 01; 128(4):325-35. PubMed ID: 12218371 [Abstract] [Full Text] [Related]
16. Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response. Atanasio A, Franklin MC, Kamat V, Hernandez AR, Badithe A, Ben LH, Jones J, Bautista J, Yancopoulos GD, Olson W, Murphy AJ, Sleeman MA, Orengo JM. J Allergy Clin Immunol; 2022 Jan 01; 149(1):200-211. PubMed ID: 34126155 [Abstract] [Full Text] [Related]
17. Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1. Mirza O, Henriksen A, Ipsen H, Larsen JN, Wissenbach M, Spangfort MD, Gajhede M. J Immunol; 2000 Jul 01; 165(1):331-8. PubMed ID: 10861069 [Abstract] [Full Text] [Related]
18. Bet v 1-like pollen allergens of multiple Fagales species can sensitize atopic individuals. Hauser M, Asam C, Himly M, Palazzo P, Voltolini S, Montanari C, Briza P, Bernardi ML, Mari A, Ferreira F, Wallner M. Clin Exp Allergy; 2011 Dec 01; 41(12):1804-14. PubMed ID: 22092996 [Abstract] [Full Text] [Related]
19. Immunoblotting in the diagnosis of cross-reactivity in children allergic to birch. Cudowska B, Kaczmarski M, Restani P. Rocz Akad Med Bialymst; 2005 Dec 01; 50():268-73. PubMed ID: 16358981 [Abstract] [Full Text] [Related]